Login to Your Account

Argos Snags $25M Series D to Move AGS-003 into Phase III

By Marie Powers
Staff Writer

Wednesday, April 25, 2012
A month after withdrawing its 2011 filing for an initial public offering (IPO), citing poor market conditions, Argos Therapeutics Inc. plied the private pump instead, raising $25 million in a Series D financing to support the launch of its Phase III ADAPT study of AGS-003 in newly diagnosed, metastatic renal cell carcinoma (mRCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription